The European Association for Haemophilia and Allied Disorders joined the European Hematology Association and other medical societies and patient advocates across disciplines to call for urgent action to make clinical trials less bureaucratic and more patient-centered, efficient and cheaper.
In the last few years, clinical trials have become more and more difficult and expensive to conduct, mainly because of the volume of bureaucratic demands involved. The rising costs and complexity lead to clinical research in Europe slowing down, fewer academic clinical trials and limited accessibility to innovative treatments.
The excessive administrative demands limit the time that clinical researchers can dedicate to their patients, a situation with potentially negative consequences for the quality of studies and the safety of patients.
You can read the full statement here
